MCH ANALYSIS RESEARCHMain site ↗
Financials

Life & Health Insurance

9 companies under coverage.

Coverage

Life & Health Insurance


Equity Research

Primerica Inc (PRI)

HOLD. 12-month probability-weighted target $298 (+8% vs spot). P/E Multiple explains 70% of Monte Carlo outcome variance.

PRIEquity ResearchMonte Carlo
10 October 2026Rating: HOLD · Fair value vs price +17.4%
Equity Research

Globe Life Inc (GL)

HOLD. 12-month probability-weighted target $173 (+6% vs spot). P/E Multiple explains 65% of Monte Carlo outcome variance.

GLEquity ResearchMonte Carlo
10 October 2026Rating: HOLD · Fair value vs price +14.5%
Equity Research

Aflac Incorporated (AFL)

HOLD. 12-month probability-weighted target $122 (+6% vs spot). P/E Multiple explains 64% of Monte Carlo outcome variance.

AFLEquity ResearchMonte Carlo
10 October 2026Rating: HOLD · Fair value vs price +1.1%
Equity Research

Prudential Financial, Inc. (PRU)

SELL. 12-month probability-weighted target $103 (-9% vs spot). Gross Margin explains 65% of Monte Carlo outcome variance.

PRUEquity ResearchMonte Carlo
10 October 2026Rating: SELL · Fair value vs price -4.0%
Equity Research

Principal Financial Group Inc (PFG)

HOLD. 12-month probability-weighted target $105 (-2% vs spot). P/E Multiple explains 48% of Monte Carlo outcome variance.

PFGEquity ResearchMonte Carlo
10 October 2026Rating: HOLD · Fair value vs price -10.4%
Equity Research

MetLife Inc (MET)

SELL. 12-month probability-weighted target $82 (-16% vs spot). Gross Margin explains 66% of Monte Carlo outcome variance.

METEquity ResearchMonte Carlo
10 October 2026Rating: SELL · Fair value vs price -21.0%
Equity Research

Unum Group (UNM)

HOLD. 12-month probability-weighted target $85 (-7% vs spot). Gross Margin explains 58% of Monte Carlo outcome variance.

UNMEquity ResearchMonte Carlo
10 October 2026Rating: HOLD · Fair value vs price -22.1%
Equity Research

CNO Financial Group Inc (CNO)

HOLD. 12-month probability-weighted target $51 (-3% vs spot). Gross Margin explains 62% of Monte Carlo outcome variance.

CNOEquity ResearchMonte Carlo
10 October 2026Rating: HOLD · Fair value vs price -22.5%
Equity Research

Brighthouse Financial, Inc. (BHF)

Rating suspended since 2026-10-03 — valuation method under review. The rating, price target and expected return are withheld until the name is re-valued; the research on the report page predates the review.

BHFEquity ResearchMonte Carlo
16 September 2026Rating: N/A
MCH ANALYSIS · All research · Research, not personal financial advicemchadvisoryservices.com ↗ · Research Standard v4 (decision-level) · Research OS ros-1.20.0 · US-listed

MCH Analysis is a general investment-research publication of MCH Advisory (Pty) Ltd. It is not personal financial advice and does not take your circumstances into account. MCH is not a licensed financial services provider or a registered investment adviser. Past performance, whether actual or simulated, does not predict future results. Subscriber Agreement | Privacy and Cookie Notice | Research Governance Policies